Cell-surface receptor for thyroid hormone and tumor cell proliferation.

Area of Science:

• Cell Biology
• Molecular Endocrinology
• Cancer Research

Background:

• Integrin αVβ3, a plasma membrane protein, acts as a novel receptor for thyroid hormone.
• Thyroid hormone signaling via integrin αVβ3 influences intracellular events, including MAPK activation and nuclear receptor modification.
• This integrin-mediated pathway is implicated in cellular proliferation, angiogenesis, and tumor growth.

Purpose of the Study:

• To elucidate the role of integrin αVβ3 as a thyroid hormone receptor.
• To investigate the mechanisms by which thyroid hormone promotes tumor cell proliferation.
• To evaluate the potential of tetraiodothyroacetic acid (tetrac) as an inhibitor of thyroid hormone-induced tumor growth.

Main Methods:

• In vitro studies using cancer cell lines (murine glioma/glioblastoma, human breast cancer MCF-7).
• Analysis of mitogen-activated protein kinase (MAPK) activation and downstream signaling.
• In vitro and preliminary in vivo experiments with tetraiodothyroacetic acid (tetrac).

Main Results:

• Integrin αVβ3 mediates thyroid hormone's proliferative effects on tumor cells.
• Thyroid hormone signaling promotes angiogenesis via basic fibroblast growth factor release.
• Tetraiodothyroacetic acid (tetrac) inhibits thyroid hormone binding to integrin αVβ3, blocking MAPK activation and tumor cell proliferation.

Conclusions:

• Integrin αVβ3 is a key mediator of thyroid hormone's pro-tumorigenic effects.
• Tetraiodothyroacetic acid (tetrac) demonstrates potential as an anticancer agent by blocking these pathways.
• Further research is warranted to explore tetrac's efficacy and the broader susceptibility of cancers to thyroid hormone-induced proliferation.